RHU ORGANOMIC

What RHU ORGANOMIC does

RHU ORGANOMIC is a French academic-industrial consortium launched in April 2023 under the France 2030 RHU (Recherche Hospitalo-Universitaire) program, co-funded by ANR, to develop functional personalized medicine (fPM) platforms for digestive cancers and lung cancers. Its scientific approach combines patient-derived organoids (PDOs) cultured from patient tumors with microfluidic tumor-on-chip devices to test drug sensitivity and identify effective treatments within clinically actionable timeframes, reporting a 62% PDO success rate, 94% genomic concordance with the original tumor, and a roughly 6-week turnaround to treatment recommendation.

The consortium operates three research platforms: CHEMOGRAM for chemotherapy response profiling, IMMUNOGRAM for immunotherapy response, and INVAGRAM for tumor invasion and metastasis assessment. The microfluidic hardware is co-developed with Okomera (Cytobot / CytoReader), and AI/ML components — including convolutional neural networks for organoid image analysis and multimodal machine learning — are developed in-house at CentraleSupélec and jointly with ORAKL Oncology, AstraZeneca and Meta AI. Clinical validation is underway through two investigator-sponsored studies, ORGANOTREAT (Phase I-II, ~50 patients) and ORGANOPREDICT (18 patients across two cohorts).

The business model is grant-funded public research, not commercial product sales. Funding flows from ANR and the France 2030 RHU program; there is no disclosed pricing, no paying customer base, and no recurring revenue. Commercialization pathways — if any — would route through partner biotechs such as ORAKL Oncology or Okomera rather than through RHU ORGANOMIC itself. Governance sits with academic institutions including Gustave Roussy, INSERM, Institut Pasteur, Université Paris-Saclay, CentraleSupélec and Grenoble Ecole de Management, with the program coordinated by Fanny Jaulin alongside Michel Ducreux, Sandra Jernström, Charles Baroud and Paul-Henry Cournède.

Name

RHU ORGANOMIC

Legal name

RHU ORGANOMIC

Website

https://rhu-organomic.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

RHU ORGANOMIC is a French academic-industrial consortium developing patient-derived organoid and microfluidic tumor-on-chip platforms to predict treatment response in digestive and lung cancers, funded by ANR and the France 2030 RHU program.

Ownership category

akta.pro rank

Product category

Functional Precision Medicine / Oncology Diagnostics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industries

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK), Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

Keywords

• Organoid drug screening
• Precision oncology diagnostics
• Tumor-on-chip devices
• Functional personalized medicine
• Microfluidic cancer assays

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Research Grant Funding: The consortium is funded by ANR (French National Research Agency) and France 2030 through a structured RHU (Hospital-University Research) grant. Revenue comes in the form of government research funding rather than commercial revenue generation.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

RHU ORGANOMIC develops functional personalized medicine tests by combining patient-derived organoids (PDOs) with microfluidic tumor-on-chip devices to deliver two predictive devices (CHEMOGRAM and IMMUNOGRAM) and one prognostic device (INVAGRAM) for digestive and lung cancers. The platform is supported by two clinical trials (ORGANOTREAT and ORGANOPREDICT) and AI-based automated image analysis. It is a research consortium rather than a commercial product vendor, funded through French government grants.

Product overview

RHU ORGANOMIC is a research consortium developing a multi-device functional precision medicine platform centered on patient-derived organoids (PDOs). The platform combines PDOs with microfluidic tumor-on-chip technology and AI-powered image analysis to deliver three distinct diagnostic/prognostic devices: CHEMOGRAM (predictive drug sensitivity screening), IMMUNOGRAM (predictive immunotherapy response assessment), and INVAGRAM (prognostic disease progression monitoring) for digestive and lung cancers. The ecosystem includes two clinical trials (ORGANOTREAT and ORGANOPREDICT), automated organogram processing via deep learning algorithms, and standardized high-throughput read-outs using microscopy-based imaging and morphometry. All devices are designed to generate personalized treatment recommendations within clinically actionable timeframes.

Differentiator

Problem solved

Functional benefit

Products and services

• CHEMOGRAM A predictive diagnostic device combining patient-derived organoids (PDOs) with tumor-on-chip technology to screen anti-cancer drugs and identify effective treatments for individual patients with digestive and lung cancers.
• IMMUNOGRAM A predictive device that assesses PDO responses to immunotherapy by co-culturing PDOs with CAR-T cells or other immune cells to evaluate cytotoxicity and immune cell activity.
• INVAGRAM A prognostic device that analyzes patient-derived organoids to predict disease progression and patient outcomes in digestive and lung cancers.
• ORGANOTREAT Trial Clinical trial focused on orienting patient treatment using patient-derived organoid (PDO) functional testing to guide therapeutic decisions for advanced cancers.
• ORGANOPREDICT Trial Clinical trial focused on monitoring patient response to treatment using patient-derived organoid (PDO) functional testing for disease progression tracking.
• Tumor-on-Chip Platform Microfluidic device platform combining patient-derived organoids (PDOs) with high-throughput robotic drug screening capabilities for standardized, automated functional assessment of PDO responses to cancer therapies.

Quantifiable outcome

• 62% PDO generation success rate from pancreatic cancer patients
• +5 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Gustave RoussycoreStrategic or Co-development PartnerGustave Roussy is a premier cancer research institute and one of Europe's leading oncology centers. They serve as a key clinical partner, hosting the ORGANOTREAT clinical trial and contributing expertise through Professor Michel Ducreux (Head of Digestive Oncology Department) and Dr. Alice Boilève.
• INSERMcoreStrategic or Co-development PartnerFrench National Institute of Health and Medical Research, the leading French public research institute in biomedical research. Contributes scientific expertise and research infrastructure to the consortium.
• Institut PasteurcoreStrategic or Co-development PartnerWorld-renowned French non-profit foundation dedicated to biological research. Charles Baroud's lab at Institut Pasteur has published significant research on cancer-on-chip models and T-cell engagement with cancer spheroids.
• Université Paris-SaclaycoreStrategic or Co-development PartnerOne of the largest universities in Europe, providing research expertise and academic resources to the consortium. Contributes to clinical trials and PDO generation through WP2.
• CentraleSupéleccoreStrategic or Co-development PartnerEngineering school affiliated with Université Paris-Saclay. Léo Fillioux from MICS at CentraleSupélec presented research on structured state space models for digital pathology at MICCAI 2023.
• AstraZenecaminorStrategic or Co-development PartnerGlobal biopharmaceutical company focused on oncology research. Collaborates with the consortium on tumor-on-chip technology development and precision oncology initiatives.
• ORAKL OncologyminorStrategic or Co-development PartnerOncology-focused company developing precision medicine solutions. Collaborates with Meta AI on applying DinoV2 foundation model to patient-derived tumor models. Contributes to tumor-on-chip designs and AI analysis.
• Grenoble Ecole de Management (GEM)minorStrategic or Co-development PartnerTop French business school studying innovation management in healthcare. Researchers Dima Louis and Janna Rose examine how actors from different organizations collaborate, technology innovation evaluation, and social impact of technologies developed by the consortium.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/rhu-organomic

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RHU ORGANOMIC